Knowledge mapping and visualization of trends of drug holiday in different solid tumours: A literature review

Abstract

Objective

The evolution of chemotherapy regimens and biologic therapies has improved survival rates for cancer patients, requiring the management of increasingly complex treatment protocols. In this context, strategies such as drug holidays (DH), intermittent therapy, and maintenance approaches have been explored to reduce therapeutic burden and mitigate long-term toxicity. However, the use of DH in oncology remains poorly defined, with no standardized protocols or clear guidelines. This review aims to evaluate the application of DH in solid tumor treatments, focusing on its definition and correlation with clinical outcomes, particularly in reducing toxicity and delaying resistance.

Data source

Systematic search of the PubMed database was conducted, with the final search executed on June 30, 2024, to identify relevant studies on DH in cancer therapy.

Data Summary

A systematic search of PubMed identified 27 relevant studies. DH was most frequently explored in colorectal cancer, with positive outcomes reported in prostate cancer, basal cell carcinoma, and thyroid cancer. However, negative outcomes were observed in renal cancer and melanoma. Definitions of DH varied widely between studies, complicating comparisons. While DH may reduce toxicity in specific cancers, such as prostate and thyroid cancers, its clinical efficacy and long-term benefits remain unclear.

Conclusion

No study has shown robust evidence supporting DH as a universally beneficial strategy. Further well-designed studies are needed to clarify its role in cancer treatment.